Dr. Jonathan Phillips joined Amgen in 2013 as a Principal Scientist and since March 2018 has served as the Global Discovery Research Lead for respiratory drug discovery where he is responsible for target identification and discovery strategies that ensure candidate molecules progress through early clinical development. Prior to joining Amgen, he worked in several respiratory discovery organizations over the course of 13 years at Schering-Plough, Merck, and Roche. Jonathan has a proven record of developing new chemical entities for respiratory diseases and has been directly responsible for five compounds selected for clinical development in asthma, COPD, and cystic fibrosis: dissociated steroid, PDE4 inhibitor, BTK inhibitor, Navarixin, and AMG 430. He also provided preclinical support for Asmanex, Dulera, and Tezepelumab. An author of over 30 peer-reviewed publications and co-inventor on two patents. Jonathan earned his Bachelor of Science from Purdue University and Ph.D. from the University of Illinois at Chicago in Chemical Engineering. He is a Licensed Professional Engineer and American Thoracic Society Fellow.